Mansoor Ahmed1, Nyaish Mansoor2, Tihami Mansoor2. 1. University Hospitals of Derby and Burton NSH Foundation Trust, Queen's Hospital Belvedere Road, Burton Upon Trent, DE13 0RB, Staffs, UK. mansoor.ahmed2@nhs.net. 2. University Hospitals of Derby and Burton NSH Foundation Trust, Queen's Hospital Belvedere Road, Burton Upon Trent, DE13 0RB, Staffs, UK.
Abstract
Eosinophilic oesophagitis is a relapsing inflammatory disorder involving oesophagus identified over 30 years ago. Diagnosis is made by upper gastrointestinal endoscopy and oesophageal biopsies. There is huge variation in management practices across the globe. Therapeutic options include the use of proton pump inhibitors, topical steroids, and elimination diet. Biologics and immunomodulator drugs are being explored but not yet recommended in children. Long-term treatment may be required to control symptoms and to prevent complications such as fibrosis/stricture. Conclusion: Even though clinicians have better understanding of eosinophilic oesophagitis, further research is warranted in exploring the unmet needs of developing a highly sensitive non-invasive biomarker for its diagnosis and response to treatment along with a robust and easily deliverable therapeutic option. What is Known: •Incidence of eosinophilic oesophagitis has increased over the recent years. •Diagnostic confirmation requires upper gastrointestinal endoscopy and therapeutic options include elimination diet and/or topical steroids. What is New: •There is a lack of consensus ion management strategy with wide variation across the globe. •There is a need to develop a highly reliable and non-invasive biomarker to diagnose eosinophilic oesophagitis and to monitor the response to treatment.
Eosinophilic oesophagitis is a relapsing inflammatory disorder involving oesophagus identified over 30 years ago. Diagnosis is made by upper gastrointestinal endoscopy and oesophageal biopsies. There is huge variation in management practices across the globe. Therapeutic options include the use of proton pump inhibitors, topical steroids, and elimination diet. Biologics and immunomodulator drugs are being explored but not yet recommended in children. Long-term treatment may be required to control symptoms and to prevent complications such as fibrosis/stricture. Conclusion: Even though clinicians have better understanding of eosinophilic oesophagitis, further research is warranted in exploring the unmet needs of developing a highly sensitive non-invasive biomarker for its diagnosis and response to treatment along with a robust and easily deliverable therapeutic option. What is Known: •Incidence of eosinophilic oesophagitis has increased over the recent years. •Diagnostic confirmation requires upper gastrointestinal endoscopy and therapeutic options include elimination diet and/or topical steroids. What is New: •There is a lack of consensus ion management strategy with wide variation across the globe. •There is a need to develop a highly reliable and non-invasive biomarker to diagnose eosinophilic oesophagitis and to monitor the response to treatment.
Authors: C Vinit; A Dieme; S Courbage; C Dehaine; C M Dufeu; S Jacquemot; M Lajus; L Montigny; E Payen; D D Yang; C Dupont Journal: Arch Pediatr Date: 2019-03-01 Impact factor: 1.180
Authors: A Papadopoulou; S Koletzko; R Heuschkel; J A Dias; K J Allen; S H Murch; S Chong; F Gottrand; S Husby; P Lionetti; M L Mearin; F M Ruemmele; M G Schäppi; A Staiano; M Wilschanski; Y Vandenplas Journal: J Pediatr Gastroenterol Nutr Date: 2014-01 Impact factor: 2.839